Scalp fibroblasts have a shared expression profile in monogenic craniosynostosis

Elena G Bochukova,1,4 Shamit Soneji,2 Steven A Wall,3 Andrew O M Wilkie1,3

ABSTRACT

Background Craniosynostosis can be caused by both genetic and environmental factors, the relative contributions of which vary between patients. Genetic testing identifies a pathogenic mutation or chromosomal abnormality in ~21% of cases, but it is likely that further causative mutations remain to be discovered.

Objective To identify a shared signature of genetically determined craniosynostosis by comparing the expression patterns in three monogenic syndromes with a control group of patients with non-syndromic sagittal synostosis.

Methods Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre—Chotzen syndrome (variations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured. The relative expression of ~47 000 transcripts was quantified on Affymetrix arrays.

Results 43S, 45 and 46 transcripts were identified in the Apert, Muenke and Saethre—Chotzen groups, respectively, that differed significantly from the controls. Forty-six of these transcripts were shared between two or more syndromes and, in all but one instance, showed the same direction of altered expression level compared with controls. Pathway analysis showed over-representation of the shared transcripts in core modules involving cell-to-cell communication and signal transduction. Individual samples from the Apert syndrome cases could be reliably distinguished from non-syndromic samples based on the gene expression profile, but this was not possible for samples from patients with Muenke and Saethre—Chotzen syndromes.

Conclusions Common modules of altered gene expression shared by genetically distinct forms of craniosynostosis were identified. Although the expression profiles cannot currently be used to classify individual patients, this may be overcome by using more sensitive assays and sampling additional tissues.

Craniosynostosis (CRS), the premature fusion of one or more of the cranial sutures, affects 1 in every 2100–2500 children and requires multidisciplinary management to address potential complications, which include raised intracranial pressure, problems with vision, hearing, breathing and feeding, learning difficulties, and significant cosmetic deformity.1

CRS is very heterogeneous, in both presentation and aetiology. Patients may variously be classified according to which sutures are fused, the association with identified genetic or environmental risk factors, the presence of additional clinical features suggestive of a syndrome, or the identification of a causative genetic mutation or chromosomal abnormality. About two-thirds of patients have non-syndromic synostosis affecting a single suture, the sagittal suture being most commonly involved (accounting for up to 50% of all individuals with CRS).1 Non-syndromic sagittal synostosis (NSS) occurs in males about four times as often as in females, but no other genetic risk factors have been consistently demonstrated, and epidemiological evidence indicates that the genetic contribution to this disorder is largely polygenic.2–4 Although intrauterine fetal head constraint is suspected to represent an important risk factor for sagittal synostosis,5 6 it is challenging to prove this in individual cases because objective data on fetal head constraint are difficult to obtain.

At the other end of the spectrum of causation, a specific genetic aetiology (either single gene mutation or chromosome abnormality) can be identified in ~21% of patients, the majority of whom have additional clinical features indicating the presence of a syndrome.6 Heterozygous mutations in the fibroblast growth factor receptor type 2 (FGFR2) and type 3 (FGFR3) genes, and the TWIST1 gene, are most commonly identified.7 The FGFR2 and FGFR3 mutations usually encode specific missense substitutions that confer gain-of-function to the mutant receptor tyrosine kinase, whereas the TWIST1 mutations are heterogeneous and result in loss-of-function (haploinsufficiency) of the encoded basic helix–loop–helix transcription factor. The most common individual CRS-related substitutions are S252W and P250R in FGFR2 (causing Apert syndrome; AS) and P250R in FGFR3 (causing Muenke syndrome; MS)8 9; TWIST1 mutations are diagnostic of Saethre—Chotzen syndrome (SCS).9

Genetic counselling for families affected with CRS is straightforward when the proband has either non-syndromic midline suture synostosis (risks are relatively low and empirical data can be used) or an identified genetic alteration (genetic testing identifies those individuals at risk). However, it is much more challenging in the minority of cases (~15–20%)6 in whom either a syndrome is suspected (based on positive family history, additional dysmorphic features or learning disability), or multiple cranial sutures are fused, but where all currently available genetic tests are negative. This situation is clearly unsatisfactory as the various aetiological possibilities in this situation (dominant, recessive, polygenic) are associated with very different recurrence risks.

To provide an alternative approach to the investigation of causation, we sought here to identify a characteristic signature, based on finding altered
patterns of mRNA expression in fibroblasts, that could potentially provide a biological marker of genetically mediated CRS. We chose to analyse fibroblasts for two reasons. Firstly, these can readily be cultured at the time of craniofacial surgery from a small biopsy sample of scalp skin, enabling the standardisation of the sampling protocol and greater simplicity for diagnostic purposes. Secondly, fibroblasts are developmentally related to osteoblasts, which have been described as ‘sophisticated fibroblasts’, and therefore represent a particularly relevant cell type in the context of CRS. By comparing the expression patterns in three of the most common genetic types of CRS with NSS cases, we have identified shared modules of altered gene expression in the syndromic groups that indicate a common pathogenetic pathway involving cell-to-cell communication and signal transduction. These results provide a starting point for a new functional method of classifying CRS based on the mRNA expression profile.

SUBJECTS AND METHODS

Patients and samples

Ethics approval for the work was obtained from the Oxfordshire Research Ethics Committee (C02.143). Patients with suspected diagnoses of AS, MS and SCS were screened for mutations in FGFR2, FGFR3 and TWIST1, respectively, by restriction digest, denaturing high-performance liquid chromatography (Transgenic WAVE System) and DNA sequencing of appropriate PCR products. Patients with TWIST1 mutations from whom we obtained samples were all reported on previously. Patients with NSS were screened for all common mutations in U133 Plus 2.0 arrays, which identify over 47 000 transcripts. We obtained samples were all reported on previously. Patients with suspected diagnoses of AS, MS and SCS were screened for mutations in FGFR2, FGFR3, and TWIST1, respectively, by restriction digest, denaturing high-performance liquid chromatography (Transgenic WAVE System) and DNA sequencing of appropriate PCR products. Patients with TWIST1 mutations from whom we obtained samples were all reported on previously. Patients with NSS were screened for all common mutations in U133 Plus 2.0 arrays, which identify over 47 000 transcripts. We obtained samples were all reported on previously.

Skin was cultured at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium (Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum (FCS; catalogue Nos A15-041 and A15-043, PAA Laboratories GmbH, Pasching, Austria) and frozen in 50% FCS for storage. Frozen cells were thawed and grown to confluence in a 75 cm2 flask before RNA extraction. All analyses were conducted on cells passage between three and five times.

RNA extraction and microarray processing

Total RNA was extracted using TRIzol (Invitrogen) following the manufacturer’s protocol. The quality of RNA samples was evaluated using the Agilent Bioanalyzer 2100 (Agilent Technologies, South Queensferry, UK). Only samples with preserved rRNA ratio (28S/18S) and no evidence for RNA degradation were analysed further.

RNA labelling and hybridisation used protocols, reagents and equipment supplied by Affymetrix, High Wycombe, UK. A 2 µg portion of total RNA from each sample was labelled with the One-Cycle cDNA Synthesis and One-Cycle Target Labelling and Control Reagent kits. Then 10 µg of the resulting biotin-labelled fragmented cRNA was hybridised to GeneChip Human Genome U133 Plus 2.0 arrays, which identify over 47000 transcripts.

After hybridisation at 45°C for 16 h (Hybridisation Oven 640), microarrays were washed and stained with streptavidin–phycoerythrin conjugate in a Fluidics Station 450, and scanned with a GeneChip Scanner 3000.

Microarray data analysis

After array scanning, quality control (QC) was performed with GCOS software (Affymetrix). All QC measures (scaling factor ≤3-fold difference within a study; S/S ratio for probe sets for GAPDH ≤3; present (P) calls in the same range for all samples in the study and RawQ below 100) were in the acceptable range for all samples. The CEL data files have been deposited in ArrayExpress (accession No E-MEXP:2256).

Affymetrix GeneChip CEL files were analysed in R (see http://www.r-project.org) using the Bioconductor packages (http://www.bioconductor.org) for QC analysis, data normalisation, hierarchical clustering, and identification of differentially expressed transcripts. Specifically, the data were normalised using Robust MultiChip Analysis, and differentially expressed genes were identified using Statistical Analysis for Microarrays (SAM) with a false discovery rate cut-off of 5%. Prediction Analysis for Microarrays (PAM) was implemented to determine if a gene set could be identified that classified the arrays correctly when cross-validation was applied. Both unsupervised and supervised two-way (genes against samples) hierarchical clustering methods were used to establish the relationships among samples and to check if the individual samples clustered together according to similarity in their expression signatures. Hierarchical clustering was performed with Genesis software using complete linkage clustering.

Gene lists produced using the above methods were subsequently imported into Ingenuity and mined by Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, US; http://www.ingenuity.com). This core gene list was analysed for gene annotation enrichment using the Database for Annotation, Visualisation and Integrated Discovery (DAVID) 2008; the enriched functional annotation terms associated with each gene were identified and listed according to their enrichment p value (http://niaid.abcc.ncifcrf.gov/). Quantitative real-time PCR

To validate the gene expression measurements independently, we performed quantitative reverse transcription PCR (RT-PCR) on three genes (HLA-DPA1, MMP1 and TGFBR2) using predesigned ABI Taqman primers, probes and amplification reagents (Assays-on-Demand; Applied Biosystems, Warrington, UK), according to the manufacturer’s instructions. Firstly, 2 µg total RNA from each subject was reverse-transcribed with the RETROscript kit (Ambion, Warrington, UK), and the cDNA was amplified by quantitative real-time PCR in an ABI 7500 PCR system (Applied Biosystems). Amplification of the GAPDH gene served as a normalisation control for each sample to correct for minor differences in RNA quality and quantity. The expression ratio was calculated using the 2-ΔΔCT method. t Tests were performed to determine significant differences in gene expression, and Fisher exact tests to compare data in 2×2 tables.

RESULTS

Expression profiling of syndromic CRS

We established primary skin fibroblast cell lines derived from scalp skin, from subjects with confirmed diagnoses of AS, MS and SCS, and control subjects with NSS. Ten samples from each diagnostic category were chosen for investigation by expression profiling.
(online supplementary table 1). RNA from the 40 subjects was hybridised to Affymetrix GeneChip U133 Plus 2.0 microarrays, which comprehensively cover the human transcriptome.

For the first stage of the analysis, we asked whether the samples could be clustered by disease category. Unsupervised clustering of all samples, based on all transcripts on the microarray, produced the dendrogram shown in figure 1. Eight of 10 AS samples located to a cluster that did not contain any NSS controls (p=0.0007), indicating that AS has the most distinctive expression profile among the four patient groups studied. By contrast, the MS and SCS samples clustered poorly, and only a minority (four MS, three SCS) were clearly discriminated from the NSS controls.

To identify the transcripts that best discriminated the syndromic patients as a whole from the NSS controls, we used SAM analysis. A total of 1044 independent probe sets, representing 863 different genes, were found to be significantly differentially expressed (online supplementary table 2). Of the 141 genes represented by two or more probe sets, the direction of change in transcription was concordant for the different probe sets in 139 cases, indicating that the great majority of changes observed are real rather than the result of statistical noise. However, supervised clustering using this gene set provided only modest improvement over unsupervised analysis, with nine of 10 AS samples clustered in a single group that contained one MS sample in addition, but no major change in the clustering of MS or SCS samples (online supplementary figure 1).

One factor that might have impeded clustering of syndromic cases from NSS controls is that the different syndromic diagnoses were associated with different expression signatures. We therefore repeated the SAM analysis, comparing each syndromic group (AS, MS, SCS) individually with the NSS controls. This analysis identified 547 (AS), 52 (MS) and 56 (SCS) independent probe sets, representing, respectively, 455 (AS), 45 (MS) and 46 (SCS) differentially expressed genes between the syndromic cases and the NSS controls (online supplementary table 3). In the previous SAM analysis of all syndromic versus NSS controls, 163 of the unique gene entries were also represented. The much larger number of probe sets identified for the AS fibroblasts presumably reflects a more widespread disturbance in cellular homeostasis, and correlates with the greater phenotypic severity of AS, with regard to both CRS and other skeletal features, compared with either MS or SCS.

Figure 1 Cluster analysis of gene expression in craniosynostosis (CRS). The dendrogram shows the results of unsupervised clustering analysis of 10 samples each of Apert syndrome (AS) (AP_01—AP_10), Muenke syndrome (MS) (M_01—M_10), Saethre—Chotzen syndrome (SCS) (SCS_01—SCS_10), and 10 non-syndromic sagittal synostosis (NSS) controls (C_01—C_10), using information from all the probe sets of the Affymetrix U133 Plus 2.0 arrays.

**Discrimination of individual syndromic samples from controls**

As an alternative approach to testing the use of these data for sample classification, we used PAM analysis for each of the syndromes compared with controls. In the case of AS, satisfactory discrimination from NSS controls (misclassification error ≤0.1) could be achieved by the measurement of 91 transcripts representing 73 genes (figure 2A). Figure 2B shows the heat map obtained when clustering using these genes. However, similar PAM analyses of MS and SCS gave unacceptably high misclassification error (>0.2) and hence poor classification potential (online supplementary figure 2).

These results indicate that, while our analytical procedure was able to distinguish individual AS from NSS samples with good confidence, it was not reliable in the case of individual MS or SCS samples.

**Identification of a common CRS syndromic expression profile**

We next asked whether the lists of unique transcripts generated using the separate SAM analyses of each syndrome compared with NSS controls, described above (online supplementary table 3), showed significant overlap. Of a total of 477 transcripts in these lists, 43 featured in two of the lists and three in all three lists (figure 3). All except one of these 46 multiply listed transcripts showed the same direction of change in the different syndromic CRS disorders relative to the NSS group, indicating that these trends were highly non-random (p=10⁻⁷). We randomly selected three transcripts significantly altered at least in the AS group for independent assessment by real-time RT-PCR; the genes chosen were HLA-DPA1 (major histocompatibility complex, class II, DP α 1), MMP1 (matrix metalloproteinase 1, interstitial collagenase; also significantly altered in SCS) and TGFB2 (transforming growth factor beta receptor II (70/80 kDa); also significantly altered in SCS). We analysed both the original samples used in the Affymetrix microarray experiment (not shown), and—for further validation on an independent set of samples—five different AS patients with P253R FGFR2 mutations and five further NSS controls (figure 4). In all cases, the results confirmed the trends originally identified in the microarray analysis, indicating that they were independent of changes in the sample, time of culture, and method of mRNA quantification.

To assess whether particular regulatory networks were enriched in the lists of discriminating transcripts for the three
syndromic conditions, we used IPA. This highlighted 22 of the 46 transcripts that had shown differential changes in more than one CRS syndrome compared with NSS controls (figure 3) as belonging to core conserved networks. ‘Network’ genes that showed increased expression in syndromic CRS are ASS1, IL15, ITGA11, PDLIM1, SHROOM3, STMN2 and TPD52L1, and those that showed decreased expression are CA12, DCBLD2, DDX17, DOCK2, HMGA2, ITGA2, ITGA6, MMP1, MT1E, NPR3, PHLD4A1, PODXL, RAPGEF2, SPRY2 and THBD. This core list was analysed for gene annotation enrichment using the DAVID algorithm. Highly significant enrichment was identified for encoded proteins involved in cell-to-cell communication and signal transduction (DCBLD2, IL15, ITGA2, ITGA6, ITGA11, NPR3, RAPGEF2, SPRY2, STMN2) (p = 0.036), with nine of the proteins integral to the plasma membrane (DCBLD2, IL15, ITGA2, ITGA6, ITGA11, PODXL, RAPGEF2, SHROOM3, THBD) (p = 0.0052).

DISCUSSION

In this work we have identified a shared alteration in expression profile in scalp fibroblasts obtained from patients with mutations in the three genes that are most commonly mutated in CRS—FGFR2, FGFR3 and TWIST1. We would expect this profile to indicate common perturbations in gene networks downstream of the mutations, providing insights into the shared pathogenesis of genetically determined CRS (as opposed to NSS, which in most cases has a different, multifactorial origin).
and 12.0-fold increase respectively), as well as the highest upregulation overall, and SHRooM3 (encoding shroom family member 3), which was upregulated 3.07/5.93-fold in AS and 3.48/4.03-fold in MS. Stathmin-like 2 is a cytosolic phospho-protein that controls microtubule assembly and dynamics, and is a marker of osteogenesis in mesenchymal stem cells; shroom 3 is an actin-binding protein that regulates the apical constriction of epithelial cells. Genes influencing cell adhesion and extracellular matrix are also prominent. ITGAV, upregulated 3.78-fold in SCS and 2.38/5.37-fold in AS, encodes half of a heterodimeric integrin (α1β1) that functions as a collagen receptor; by contrast, genes encoding two other integrin subunits, ITGA2 and ITGA6, as well as MMP1 (encoding matrix metalloproteinase 1 (an interstitial collagenase)), were downregulated in the same two disorders. SPP1 encoding osteopontin, the principal phosphorylated glycoprotein of bone, was downregulated fourfold in AS and 5.1-fold in MS, and SPRY2, encoding sprouty 2, a negative regulator of FGF signalling, was downregulated 2.0-fold in MS and 2.9-fold in SCS.

Whereas these data point to a major influence of CRS mutations on downstream gene expression, the SAM analysis did not highlight any significant changes in expression of the mutated genes themselves (TwiSt1, FGF2R or FGFR3) in these samples. In the PAM analysis, however, two FGF2R probe sets were selected among the 73 genes giving the best discrimination of AS from NSS controls (figure 1). Interestingly, FGF2R showed relative upregulation in AS cells, which contrasts with previous reports that FGF2R/Fgfr2 expression is either unchanged or reduced in the cranial sutures of AS individuals or mouse models. Clearly fibroblast culture represents a different cellular milieu from the cranial suture, and we do not expect a simple equivalence of gene expression profiles between the two situations. Nevertheless, it is likely that the altered cellular properties of fibroblasts reflect endogenous properties of the suture, hence the genes that show altered expression are plausible candidates in which mutations may cause CRS. Supporting this, heterozygous mutations in TGBFR2, which showed reduced expression in AS (2.17–2.94-fold; figure 4) and MS (2.08-fold), cause Loey’s–Dietz syndrome, in which CRS sometimes occurs.

Previously, three other studies have profiled gene expression in CRS using microarray analysis of transcripts. These studies investigated different cell types compared with the present work and used diverse array platforms. Carinci et al. studied periosteal fibroblasts of three patients (AS with FGF2R2 P253R mutation, Crouzon syndrome with FGF2R2 G338R mutation, and Crouzon syndrome without an identified mutation), using a 19K cDNA array platform. Fanganiello et al. studied periosteal fibroblasts in seven AS patients with the FGF2R2 S252W mutation, using the CodeLink array platform. Coussens et al. used tissue samples from a combination of fused, fusing and unfused sutures in five patients (AS with S252W mutation, and three sagittal and one unicoronal synostosis without identified mutations), using the same Affymetrix platform as in the present work. By contrast, we chose to undertake expression profiling in fibroblasts (see the Introduction); the relative simplicity of harvesting and culture enabled us to sample a much larger number of patients than described in the previous studies.

We compared the gene lists generated from the two larger previously published studies (262 genes in Fanganiello et al. and 651 in Coussens et al.) with our list of 865 differentially expressed genes between monogenic CRS and NSS controls (online supplementary table 2). No genes were found in common to all of the lists, and the overlap of genes shared by
any two lists was modest (online supplementary figure 3). In none of the three comparisons did the shared transcripts show changes in a consistent direction for syndromic cases or fusing sutures more often than expected by chance. Hence we conclude that, presumably owing to substantial differences in sample sources and methodology, it is not appropriate to combine the results of any of these studies. Notably, our experimental design used fibroblasts from patients with NSS as the ‘control’ comparator group; we did not explore whether these NSS samples might themselves show consistent differences from a non-CRS population. Such an effect could have obscured some of the features of the monogenic CRS expression profile compared with the normal state.

In summary, we have identified an expression profile of syndromic CRS in scalp fibroblasts that exhibits shared features across three of the most common genetically determined syndromes (AS, MS, SCS) that distinguish these samples from NSS controls. As well as demonstrating shared signalling modules in these three syndromes, this observation supports our original reasoning that NSS has a distinct pathological origin. The syndromic CRS profile is robust, based on the consistent direction of change in expression, and replication in independent samples. Although, with the exception of AS, this profile cannot currently distinguish individual samples from NSS, improved sensitivity of the cDNA assay (for example, using deep sequencing) should increase signal specificity. Further refinements to this approach may provide a method of classifying individual samples into dichotomous groups with either high or low genetic load, which would assist genetic counselling even when a causative mutation has not been found.

Acknowledgements We thank the subjects and their families for their participation in this work, Sue Butler for excellent assistance with cell culture, and Chris Babbs and Steve Twigg for comments on the manuscript. We are very grateful to Cordelia Langford (Wellcome Trust Sanger Institute), who helped to pilot an earlier phase of the work reported here.

Funding This work was funded by the Medical Research Council (support to SS) and the Wellcome Trust (Programme Grant 078668 to ADW).

Competing interests None.

Ethical approval This study was conducted with the approval of the Oxfordshire Research Ethics Committee (C02.143).

Contributors EB designed experiments, analysed data, wrote the paper. SS analysed data, AWM coordinated obtaining samples, ADW designed the study, analysed data and wrote the paper.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Cohen MM Jr, Maclean RE, eds. Craniosynostosis: diagnosis, evaluation, and management. 2nd rev edn. Oxford: Oxford University Press, 2000.

Lajeunie E, Le Merler M, Bonäti-Pelle C, Marchac D, Renier D. Genetic study of scaphocephaly. Am J Med Genet 1996;62:282–5.

A. Lajeunie E, Cerrag M, Arnaud E, Renier D. Genetic considerations in nonsyndromic midline craniosynostoses: a study of twins and their families. J Neurosurg 2003;99:1371–2.

Bochukova EG, Hansen RM, Taylor IB, Ramar-Eiya SV, Byren JC, Wall SA. Prevalence and complications of single-gene and bi-allelic syndromes in craniosynostosis. J Med Genet 2009;46:341–7.

Lester T. Clinical dividends from the molecular genetic diagnosis of craniosynostosis. Orthod Craniofac Res 2001;4:7416–22.

Bochukova EG, Brugger SM, Ishii M, Biolo D, Wall SA, Lyons KM, Wilkie ADW, Maxon RE Jr. Cell mixing at a neural crest-mesodermal boundary and deficient ephrin-ephrin signalling in the pathogenesis of craniosynostosis. Hum Mol Genet 2006;15:1319–28.

Iseki S, Wilkie AOM, Morriss-Kay GM. Fgfr1 and Fgfr2 have distinct differentiation and proliferation-related roles in the developing mouse skull vault. Development 1999;126:661–20.

Guennoc H, Kaabchech K, Mee SL, Marie PJ. A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype caused by twist haploinsufficiency in the Saethre-Chotzen syndrome. Hum Mol Genet 2005;14:1429–39.

Connerney J, Andreuva V, Leshem Y, Mercado MA, Dowell K, Yang X, Lindner V, Friesel R, Spencer DB. Twist1 homodimers enhance FGF responsiveness of the cranial sutures and promote suture closure. Dev Biol 2008;318:253–34.

Connerney J, Ohtani K, Ohata K, Kuroda T, Nakamura M. Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix proteins. Mol Cell Biol 2001;21:7416–28.

Chellinii C, Greninger C, Cochet D, Scheideler M, Trajanozski A, Altuld G, Dari C, Arni E. Zahnmin-like 2, a developmentally-associated neuronal marker, is expressed and modulated during osteogenesis of human mesenchymal stem cells. Biochem Biophys Res Commun 2008;374:64–8.

Nishimura T, Takeichi M. Shroom3-mediated recruitment of Rho kinases to the cell cortex suggests a basis for differences in their cranial phenotypes. J Neurosci 2001;21:1310–17.

Britto JA, Moore RL, Evans RD, Hayward RD, Jones BM. Negative autoregulation of fibroblast growth factor receptor 2 expression characterizing cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes. J Neurosurg 2001;95:680–73.

Holmes G, Rothstchild G, Roy UB, Deng CX, Mansukhani A, Basilo C. Early onset of craniosynostosis in an Asian OM patient: a case report. J Craniofac Surg 2006;17:741–5.

Maliakel MG, El-Naggar A, Forouhar F, Tarin D, Awad A. Clinical presentation and management of Apert syndrome: a review of 15 years experience. J Craniofac Surg 2005;16:422–9.

Kress W, Schopp C, Lieg B, Petersen B, Buise-Ratzka M, Kunz J, Reinert H, Schäfer W-D, Sold J, Hoppe P, Palmke J, Juesen A, Sierenzen N, Krauss J, Dollmann H. Saethre-Chotzen syndrome caused by TWIST1 gene mutations: functional differentiation from Muenke craniosynostosis syndrome. Eur J Hum Genet 2006;14:39–48.

Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000;289:1501–4.

Woods RH, Ul-Haq E, Wilkie AOM, Jayamohan J, Richards PG, Johnson D, Lester T, Wall SA. Reappraisal for intracranial hypertension in TWIST1 confirmed Saethre-Chotzen syndrome: a 15 year review. Plast Reconstr Surg 2000;105:1010–10.

Izirracy RA, Hobbs B, Collins F, Beaizer-Barclay YD, Antoniello SK, Schur J, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:248–64.

Toshger VG, Tishbirani R. Sigma-1: a surveillance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116–21.

Tishbirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunk centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567–72.

Sturn A, Quackenbush J, Trajanoski Z. Genetic cluster analysis of microarray data. Bioinformatics 2002;18:207–8.

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.